Skip to content
DataLookout
Menu

NCT07925983

A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants

StatusRecruiting
PhasePhase 1
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Maximum Serum Concentration (Cmax) of trosunilimab
Timeframe: Up to 7 Days
Time to Cmax (Tmax) of trosunilimab
Timeframe: Up to 7 Days
Concentration at Week 4 (Cwk4) of trosunilimab
Timeframe: Week 4
Area under the serum concentration-time curve from Week 0 to 4 (AUC0-4wk) of trosunilimab
Timeframe: Weeks 0 to 4
Number of Participants Experiencing Adverse Events
Timeframe: Up to 140 Days

Arms and interventions

Arm 1: Trosunilimab IVActive comparator

Participants will receive an intravenous (IV) trosunilimab dose

Arm 2: Trosunilimab SCActive comparator

Participants will receive subcutaneous (SC) injection doses of trosunilimab

Drugs: Trosunilimab

Sites

1 site in 1 country

  • Acpru /Id# 286224Grayslake, Illinois, United States